Montefiore Medical Center

Teams from France and Germany disputed the notion that the 21-gene signature is needed to identify low-risk breast cancer patients who can be spared chemotherapy.

Researchers used the 21-gene expression assay to find individuals at lowest risk of breast cancer recurrence, who were spared adjuvant chemotherapy.

The funding will support work identifying the mechanisms underlying the differential responses among pediatric and adult ALL patients to therapy.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

The technology from Montefiore Medical Center relates to tumor-specific mutations in the genes PIK3CA and PTEN that can be useful in predicting patient non-response to EGFR inhibitors.

People in the News

Premium

Stephane Perrey, Kazuo Tokushige, Allen Bombard, Jorge Leon

People in the News

Premium

Frank Witney, Allen Bombard

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

Nature News writes that researchers are still wrangling over the role of the p-value.

In Nature this week: paternal age associated with de novo mutations in children, and more.